Publications
Detailed Information
Wild-type p53 enhances the cytotoxic effect of radionuclide gene therapy using sodium iodide symporter in a murine anaplastic thyroid cancer model
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Yong Jin | - |
dc.contributor.author | Chung, June-Key | - |
dc.contributor.author | Kang, Joo Hyun | - |
dc.contributor.author | Jeong, Jae Min | - |
dc.contributor.author | Lee, Myung Chul | - |
dc.contributor.author | Lee, Dong Soo | - |
dc.date.accessioned | 2012-07-03T07:57:12Z | - |
dc.date.available | 2012-07-03T07:57:12Z | - |
dc.date.issued | 2010-02 | - |
dc.identifier.citation | EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING; Vol.37 2; 235-241 | ko_KR |
dc.identifier.issn | 1619-7070 | - |
dc.identifier.uri | https://hdl.handle.net/10371/78298 | - |
dc.description.abstract | To evaluate the role of p53 in radionuclide gene therapy, we investigated the cytotoxic effect of (131)I and (188)Re following cotransfection of the sodium iodide symporter (NIS) and wild-type p53 (wt-p53) genes into cancer cells. The NIS gene was transfected to human anaplastic thyroid carcinoma cells (ARO) expressing mutant p53 (mt-p53) using liposomes. The uptakes of (125)I and (188)Re were measured in the transfected (ARO-N) and wild-type cell lines (ARO). A recombinant adenovirus-5 vector containing a CMV promoter and wt-p53 cDNA, called Ad-p53, was established and transduced to ARO and ARO-N cells. After incubating cells with (131)I and (188)Re, the survival rate of each cell line was measured using a clonogenic assay. For radionuclide gene therapy in an animal model, Ad-p53 was injected directly into ARO and ARO-N tumours which were transplanted to nude mice. Two days later, (188)Re or saline was injected intraperitoneally into the mice, and the tumours were measured using a calliper for 4 weeks. In ARO-N cells, the uptakes of (125)I and (188)Re were 505.16 +/- 21.30 pmol/10(6) cells and 13,875.20 +/- 504.85 cpm/10(6) cells at 30 min, respectively. There was no difference between the survival rates of ARO cells and ARO-N cells after incubation with (131)I or (188)Re. When Ad-p53 was transduced to ARO-N cells, the survival rate of wt-p53-expressing ARO-N cells incubated with (131)I (18.5 MBq/5 ml) and (188)Re (18.5 MBq/5 ml) decreased to 48.8 +/- 18.4% and 32.6 +/- 23.5%, respectively. In the nude mice experiment, ARO and ARO-N tumours gradually grew up to six to eight times larger than the initial volume. ARO and ARO-N tumours transduced with Ad-p53 continued to grow. However, the ARO-N tumours treated with Ad-p53 and 185 MBq of (188)Re regressed to 20% of the initial volume. Growth of ARO-N tumour treated with (131)I or (188)Re was significantly inhibited by Ad-p53 transduction in vivo as well as in vitro. Transfection of the NIS gene into human anaplastic thyroid cancer induced the accumulation of beta-emitter radionuclides, and cotransfection with a wt-p53 gene enhanced the cytotoxic effect. | ko_KR |
dc.description.sponsorship | This work was supported by a Korea Research
Foundation Grant funded by the Korean Government (MOEHRD) (KRF-2003-E-00168) | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | SPRINGER | ko_KR |
dc.subject | NIS | ko_KR |
dc.subject | Radionuclide gene therapy | ko_KR |
dc.subject | Anaplastic thyroid cancer | ko_KR |
dc.subject | (188)Re | ko_KR |
dc.subject | wt-p53 | ko_KR |
dc.subject | (131)I | ko_KR |
dc.title | Wild-type p53 enhances the cytotoxic effect of radionuclide gene therapy using sodium iodide symporter in a murine anaplastic thyroid cancer model | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 이용진 | - |
dc.contributor.AlternativeAuthor | 정준기 | - |
dc.contributor.AlternativeAuthor | 강주현 | - |
dc.contributor.AlternativeAuthor | 정재민 | - |
dc.contributor.AlternativeAuthor | 이동수 | - |
dc.contributor.AlternativeAuthor | 이명철 | - |
dc.identifier.doi | 10.1007/s00259-009-1251-5 | - |
dc.citation.journaltitle | EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | - |
dc.description.citedreference | Hsieh YJ, 2007, ANTICANCER RES, V27, P2515 | - |
dc.description.citedreference | D`Avenia P, 2006, CANCER LETT, V231, P102, DOI 10.1016/j.canlet.2005.01.033 | - |
dc.description.citedreference | Lopez-Crapez E, 2005, BRIT J CANCER, V92, P2114, DOI 10.1038/sj.bjc.6602622 | - |
dc.description.citedreference | Lee YJ, 2004, THYROID, V14, P889 | - |
dc.description.citedreference | Freytag SO, 2004, EXPERT OPIN BIOL TH, V4, P1757, DOI 10.1015/14712598.4.11.1757 | - |
dc.description.citedreference | Lee WW, 2003, ONCOL REP, V10, P845 | - |
dc.description.citedreference | Dohan O, 2003, ENDOCR REV, V24, P48, DOI 10.1210/er.2001-0029 | - |
dc.description.citedreference | Heltemes LM, 2003, CANCER GENE THER, V10, P14 | - |
dc.description.citedreference | Carlin S, 2002, NUCL MED BIOL, V29, P729 | - |
dc.description.citedreference | Chung JK, 2002, J NUCL MED, V43, P1188 | - |
dc.description.citedreference | Dadachova E, 2002, NUCL MED BIOL, V29, P13 | - |
dc.description.citedreference | Sasaki R, 2001, INT J RADIAT ONCOL, V51, P1336 | - |
dc.description.citedreference | Huang M, 2001, CANCER GENE THER, V8, P612 | - |
dc.description.citedreference | Haberkorn U, 2001, J NUCL MED, V42, P317 | - |
dc.description.citedreference | Kawabe S, 2001, INT J RADIAT BIOL, V77, P185 | - |
dc.description.citedreference | Colletier PJ, 2000, INT J RADIAT ONCOL, V48, P1507 | - |
dc.description.citedreference | Nakamoto Y, 2000, J NUCL MED, V41, P1898 | - |
dc.description.citedreference | Arturi F, 2000, EUR J ENDOCRINOL, V143, P623 | - |
dc.description.citedreference | Smit JWA, 2000, THYROID, V10, P939 | - |
dc.description.citedreference | Nagayama Y, 2000, J CLIN ENDOCR METAB, V85, P4081 | - |
dc.description.citedreference | Boland A, 2000, CANCER RES, V60, P3484 | - |
dc.description.citedreference | Horowitz J, 1999, CURR OPIN MOL THER, V1, P500 | - |
dc.description.citedreference | Mandell RB, 1999, CANCER RES, V59, P661 | - |
dc.description.citedreference | Shimura H, 1997, ENDOCRINOLOGY, V138, P4493 | - |
dc.description.citedreference | Siles E, 1996, BRIT J CANCER, V73, P581 | - |
dc.description.citedreference | LAMIOKI H, 1994, RADIOCHIM ACTA, V65, P39 | - |
dc.description.citedreference | MAHESHWARI YK, 1981, CANCER, V47, P664 | - |
dc.description.tc | 1 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.